Mersana Therapeutics MRSN releases its next round of earnings this Friday, August 07. Here's Benzinga's essential guide to Mersana Therapeutics's Q2 earnings report.
Earnings and Revenue
Based on management's projections, Mersana Therapeutics analysts modeled for EPS at $-0.3 per share on sales of $300.00 thousand. In the same quarter last year, Mersana Therapeutics reported EPS of $-0.36 on sales of $202.00 thousand. The analyst consensus estimate would represent a 16.67% increase in the company's earnings. Mersana Therapeutics's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|
| EPS Estimate | -0.37 | -0.38 | -0.37 | -0.38 |
| EPS Actual | -0.35 | -0.34 | -0.35 | -0.36 |
| Revenue Estimate | 390.00 K | 290.00 K | 290.00 K | 740.00 K |
| Revenue Actual | 11.00 K | 42.00 K | 844.00 K | 202.00 K |
Stock Performance
Over the last 52-week period, shares are up 555.95%. Given that these returns are positive, long-term shareholders can be satisfied going into this earnings release.
Looking at these results, shareholders should be feeling unsatisfied with these results.
Don't be surprised to see the stock move on comments made during its conference call. Mersana Therapeutics is scheduled to hold the call at 08:00:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/wytvxume
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
